AveXis Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
Biotechs Bounce Off Bottom On Novartis Deal But Fade Later In The Day
Article By: Rod Raynovich Monday, April 9, 2018 7:49 PM EST
Normally this kind of M&A news would be an opportunity to load up on biotechs but technicals are still weak and crosscurrents from economic and macro news create a risk-off sentiment.
In this article: NVS, FBT, AGIO, AVXS Also: IBB, SGMO, XBI, BLUE, ONCE, CLLS, EDIT, NTLA, CRSP
Read
After Former Citron Short Target AveXis Gets Bought, Analyst Asks 'who's Next'
Article By: The Fly Monday, April 9, 2018 11:25 AM EST
AveXis shares are surging after the gene therapy researcher announced an agreement to be acquired by Novartis for $218 per share, or $8.7billion in cash. This comes two years after Citron Research made a short call of a AveXis $5 price target.
In this article: NVS, AVXS Also: BMRN, VYGR, BLUE, ONCE, RGNX
Read
AveXis Announces Proposed Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire Tuesday, January 16, 2018 11:28 AM EST
AveXis, Inc. today announced that it intends to offer and sell, subject to market conditions, up to $400 million of shares of its common stock in an underwritten public offering.
In this article: AVXS
Read
AveXis Inc.: Shares Spike On Positive Top Line Results For AVXS-101 Despite Q4 Loss
Article By: TickerTV Friday, March 17, 2017 9:00 AM EST
AVXS opened trading yesterday at $74.46, which was down from the previous day’s trading close of $74.88. Shares closed trading yesterday at $72.78 and spiked up after market to $81.50, equivalent to a 12% increase from the closing price.
In this article: AVXS
Read
AveXis Slides After Biogen, Ionis SMA Drug Approval
Article By: The Fly Tuesday, December 27, 2016 2:12 PM EST
Shares of AveXis are slipping after Biogen and Ionis Pharmaceuticals received FDA approval for Spinraza, their treatment for spinal muscular atrophy, or SMA.
In this article: BIIB, IONS, AVXS
Read
Five Biotech IPOs Lead The Way In 2016
Article By: Don Dion Friday, November 25, 2016 10:33 AM EST
While the IPO market was relatively weak in 2016 overall, biopharma IPOs excelled. We have been particularly impressed with AveXis, Clearside Biomedical, Protagonist Therapeutics, Reata Pharma, and bluebird bio.
In this article: BLUE, AVXS, RETA, PTGX, CLSD
Read
AveXis IPO: We Like This Goldman-Led Deal
Article By: Don Dion Tuesday, February 9, 2016 11:34 AM EST
AveXis Incorporated expects to raise $76.5 million in its upcoming IPO. AVXS will offer 4.25 million shares at an expected price range of $19 to $21.
In this article: AVXS Also: NVS, VYGR, PTCT, IONS
Read
1 to 7 of 7 Posts